Roy S. Herbst

92.8k citations

583 papers · 50.9k indexed · 24 hit papers · h-index 102

Impact in

Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 400
- Cancer Immunotherapy and Biomarkers 150
- Lung Cancer Research Studies 120
- Colorectal Cancer Treatments and Studies 97
- HER2/EGFR in Cancer Research 51
Pulmonary and Respiratory Medicine 361
- Lung Cancer Treatments and Mutations 314
- Lung Cancer Diagnosis and Treatment 97

Co-authors: Chris Boshoff Daniel Morgensztern John V. Heymach Scott M. Lippman David H. Johnson Alan Sandler David L. Rimm Kurt A. Schalper
Journals: Journal of Clinical Oncology (176 papers)Journal of Thoracic Oncology (53 papers)Clinical Cancer Research (47 papers)Annals of Oncology (34 papers)Clinical Lung Cancer (25 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Roy S. Herbst

568 papers receiving 49.8k citations

Hit Papers

15 papers align trajectories log scale

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC 2023 · 263 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 New England Journal of Medicine
2022 Nature Reviews Drug Discovery
2022 Journal of Clinical Oncology
2021 Nature Reviews Clinical Oncology
2021 Journal of Thoracic Oncology
2021 Nature Medicine
2019 Nature Medicine
2019 Clinical Cancer Research
2018 Nature
2018 Clinical Cancer Research
2017 JAMA Oncology
2015 The Lancet
2015 JAMA Oncology
2013 Laboratory Investigation
2008 New England Journal of Medicine
2007 Clinical Cancer Research
2005 Journal of Clinical Oncology
2005 Journal of Clinical Oncology
2005 Journal of Clinical Oncology
2004 International Journal of Radiation Oncology*Biology*Physics
2004 Journal of Clinical Oncology
2004 Journal of Clinical Oncology
2004 Journal of Clinical Oncology
2003 JAMA

Peers

Countries citing papers authored by Roy S. Herbst

Since Specialization

Citations

This map shows the geographic impact of Roy S. Herbst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy S. Herbst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy S. Herbst more than expected).

Fields of papers citing papers by Roy S. Herbst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy S. Herbst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy S. Herbst. The network helps show where Roy S. Herbst may publish in the future.

Co-authors

The 25 scholars most cited alongside Roy S. Herbst, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roy S. Herbst Line = papers co-authored together Roy S. Herbst links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403) Clinical Cancer Research ·Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara	2022	31
2	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling Clinical Cancer Research ·Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm	2020	83
3	Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes Clinical Cancer Research ·Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt A. Schalper, Roy S. Herbst Hit paper breakdown →	2019	470
4	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy Clinical Cancer Research ·Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm	2019	225
5	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA Clinical Cancer Research ·Sarah B. Goldberg, Azeet Narayan, Adam J. Kole, Roy H. Decker, Jimmitti Teysir, Nicholas Carriero, Angela Lee, Roxanne Nemati, Sameer K. Nath, Shrikant Mane, Yanhong Deng, Nitin Sukumar, Daniel Zelterman, Daniel J. Boffa, Katerina Politi, Scott Gettinger, Lynn D. Wilson, Roy S. Herbst, Abhijit A. Patel Hit paper breakdown →	2018	317
6	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes Clinical Cancer Research ·Mehmet Altan, Vasiliki Pelekanou, Kurt A. Schalper, Maria Toki, Patricia Gaule, Konstantinos Syrigos, Roy S. Herbst, David L. Rimm	2017	108
7	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer Clinical Cancer Research ·Franz Villarroel‐Espíndola, Xiaoqing Yu, Ila Datar, Nikita Mani, Miguel F. Sanmamed, Vamsidhar Velcheti, Konstantinos Syrigos, Maria Toki, Hongyu Zhao, Lieping Chen, Roy S. Herbst, Kurt A. Schalper	2017	162
8	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics ·Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Dennis Ruder, Carmen Behrens, Li Shen, Neda Kalhor, Juhee Song, J. Jack Lee, Jing Wang, Ximing Tang, Roy S. Herbst, Shinichi Toyooka, Luc Girard, John D. Minna, Jonathan M. Kurie, Ignacio I. Wistuba, Julie Izzo	2017	84
9	Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research Clinical Cancer Research ·Stephanie R. Land, Benjamin A. Toll, Carol M. Moinpour, Sandra A. Mitchell, Jamie S. Ostroff, Dorothy K. Hatsukami, Sonia A. Duffy, Ellen R. Gritz, Nancy A. Rigotti, Thomas H. Brandon, Sheila A. Prindiville, Linda Sarna, Robert A. Schnoll, Roy S. Herbst, Paul M. Cinciripini, Scott J. Leischow, Carolyn M. Dresler, Michael C. Fiore, Graham Warren	2016	57
10	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer Clinical Cancer Research ·Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Joseph McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F. Sanmamed, Lieping Chen, Roy S. Herbst, David L. Rimm	2016	160
11	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Clinical Cancer Research ·Monique B. Nilsson, Uma Giri, Jayanthi Gudikote, Ximing Tang, Wei Lü, Hai T. Tran, You-Hong Fan, Andrew B. Koo, Lixia Diao, Pan Tong, Jing Wang, Roy S. Herbst, Bruce E. Johnson, Andy Ryan, Alan Webster, Philip Rowe, Ignacio I. Wistuba, John V. Heymach	2015	10
12	Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis Cancer Research ·Bing Ma, Erica L. Herzog, Chun Geun Lee, Xueyan Peng, Chang-Min Lee, Xiaosong Chen, Sara Rockwell, Ja Seok Koo, Harriet M. Kluger, Roy S. Herbst, Mario Sznol, Jack A. Elias	2014	67
13	Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells Clinical Cancer Research ·Hirohito Yamaguchi, Jennifer L. Hsu, Chun‐Te Chen, Ying‐Nai Wang, Ming‐Chuan Hsu, Sam S. Chang, Yi Du, How-Wen Ko, Roy S. Herbst, Mien‐Chie Hung	2013	110
14	A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research ·David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O’Bryant, Alex Vo, Kevin Klucher, Roy S. Herbst, Sabine Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, Antonio Jimeno	2012	134
15	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 Clinical Cancer Research ·Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, David R. Gandara	2012	38
16	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy Cancer Research ·Fei Yang, Ximing Tang, Erick Riquelme, Carmen Behrens, Monique B. Nilsson, Uma Giri, Marileila Varella‐Garcia, Lauren A. Byers, Heather Lin, Jing Wang, Maria Gabriela Raso, Luc Girard, Kevin R. Coombes, J. Jack Lee, Roy S. Herbst, John D. Minna, John V. Heymach, Ignacio I. Wistuba	2011	51
17	A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors Clinical Cancer Research ·Roy S. Herbst, Razelle Kurzrock, David S. Hong, Manuel Valdivieso, Cheng‐Pang Hsu, Lovely Goyal, Gloria Juan, Yuying C. Hwang, F. Susan Wong, John S. Hill, Greg Friberg, Patricia LoRusso	2010	111
18	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer Clinical Cancer Research ·Emer O. Hanrahan, Anderson J. Ryan, Helen Mann, S. Kennedy, Peter Langmuir, Ronald B. Natale, Roy S. Herbst, Bruce E. Johnson, John V. Heymach	2009	69
19	Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Lee S. Rosen, Razelle Kurzrock, Marilyn Mulay, A. Van Vugt, Michelle Purdom, Chaan S. Ng, J. M. Silverman, Antonis D. Koutsoukos, Yu-Nien Sun, Michael Bass, Ren Xu, Anthony Polverino, Jeffrey S. Wiezorek, David Chang, Robert S. Benjamin, Roy S. Herbst	2007	152
20	Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer Journal of Clinical Oncology ·Michael A. Carducci, Luna Musib, Merrill S. Kies, Роберто Пили, Mylene T. Truong, Julie R. Brahmer, Patricia E. Cole, Rana Sullivan, Jeanne R. Riddle, Jill Schmidt, Nathan Enas, Vikram Sinha, Donald Thornton, Roy S. Herbst	2006	150

About Roy S. Herbst

Roy S. Herbst is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Hepatology, having authored 583 papers that have together received 50.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (314 papers), Cancer Immunotherapy and Biomarkers (150 papers), Lung Cancer Research Studies (120 papers), Colorectal Cancer Treatments and Studies (97 papers), Lung Cancer Diagnosis and Treatment (97 papers), Cancer Genomics and Diagnostics (81 papers), HER2/EGFR in Cancer Research (51 papers) and Angiogenesis and VEGF in Cancer (46 papers). The work is most often cited by research in Oncology (31.9k citations), Pulmonary and Respiratory Medicine (26.5k citations), Cancer Research (9.2k citations), Immunology (5.5k citations) and Molecular Biology (17.0k citations). Roy S. Herbst has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Chris Boshoff, Daniel Morgensztern, John V. Heymach, Scott M. Lippman, David H. Johnson, Alan Sandler, David L. Rimm, Kurt A. Schalper, Steven D. Averbuch and Vincent A. Miller. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Cancer Research, Annals of Oncology and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact